Compare

Koninklijke Philips/$PHG

1D1W1M3M6MYTD1Y5YMAX

About Koninklijke Philips

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
Ticker
$PHG
Sector
Health
Primary listing
NYSE
Employees
63,909
Headquarters
Amsterdam, Netherlands
Website
www.philips.com

PHG Metrics

BasicAdvanced
$29B
27.74
$1.08
0.81
$0.84
2.80%

What the Analysts think about PHG

Analyst ratings (Buy, Hold, Sell) for Koninklijke Philips stock.
Analyst projections of the future price of Koninklijke Philips stock.

Bulls say / Bears say

Equipment order intake rose 8% in Q3, with Diagnosis & Treatment orders up nearly 20% and the equipment order book increasing year on year. That gives Philips a stronger pipeline to convert into future sales. (Philips)
Q3 adjusted EBITA margin widened by 70 basis points to 13%, while free cash flow increased to €384 million. Philips also delivered €427 million of productivity savings in the first nine months, showing progress in improving profitability despite cost inflation. (Philips)
Personal Health sales grew 8% and Connected Care sales grew 5% in Q3. Growth across these businesses helps balance Philips’ exposure to softer demand in parts of medical imaging. (Philips)
The proposed €288 million US Justice Department settlement is only one part of the Respironics overhang: the State Attorneys General investigation remains unresolved, and restrictions on some US respiratory-device sales remain tied to the FDA consent decree. Further legal or regulatory costs could therefore persist. (MedTech Dive, Philips)
Diagnosis & Treatment sales were flat in Q3 as weaker China sales and ultrasound shipment delays offset growth elsewhere. The delayed ultrasound sales are expected in Q4 and early 2027, leaving near-term growth dependent on execution and timing. (Citeline, Philips)
Philips’ 2026 margin outlook includes about a one-percentage-point benefit from US tariff refunds, while its free-cash-flow outlook includes a net €200 million benefit. Those one-off gains make the headline targets less representative of underlying recurring performance. (Philips)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

PHG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

PHG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

PHG News

AllArticlesVideos

Philips Reports Strong Customer Demand, Improved Profitability

Benzinga1 week ago

What Koninklijke Philips (PHG) Said on Its Q3 Earnings Call

MarketBeat1 week ago

Philips Sales Rise Amid Product Recall Agreement

WSJ1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.